Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Is the MS community ready to promote brain health? Reception and Symposium
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
Unique association of Waldenström macroglobulinemia with optic neuritis and monoclonal T cell expansion.
Neuron-specific SALM5 limits inflammation in the CNS via its interaction with HVEM.
Diplomatic Assistance: Can Helminth-Modulated Macrophages Act as Treatment for Inflammatory Disease?
PML in a patient treated with dimethyl fumarate from a compounding pharmacy.
Oligodendrogliopathy in Multiple Sclerosis: Low Glycolytic Metabolic Rate Promotes Oligodendrocyte Survival.
The effects of diet on the severity of central nervous system disease: One part of lab-to-lab variability.
Perk Ablation Ameliorates Myelination in S63del-Charcot-Marie-Tooth 1B Neuropathy.
Brain-gut axis and pentadecapeptide BPC 157. Theoretical and practical implications.
In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity.
Pediatric Multiple Sclerosis.
Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis.
Policy: NIH to balance sex in cell and animal studies.
Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
Neurotrophic and Neuroprotective effects of muscle contraction.
Multi-parametric quantitative MRI of normal appearing white matter in multiple sclerosis, and the effect of disease activity on T2.
The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies.
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
Hematopoietic stem cell transplantation for MS: extraordinary evidence still needed.
Alpha/beta interferon is a neuronal growth factor.
Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease.
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets.
Neurovascular coupling in patients with relapsing-remitting multiple sclerosis.

Pages